The Global Minimally Invasive Biopsy Technologies Market is projected to reach USD 3.98 billion in 2027. The market is expected to be driven due to a higher proliferation of the minimally invasive surgical procedures in biopsy testing and an extensive rise in the rate of breast and lung cancers globally. Around 66% of the total initial breast biopsies performed in North America are minimally invasive breast biopsies (MIBB).
The extensive proliferation of the minimally invasive surgical technologies and extensive rise in the requirement of biopsy tests to diagnose cancerous cells and identifying infectious, autoimmune disorders and inflammatory cases. Early detection of the cancers and higher precision compared to incisional and excisional biopsies have been the constant driving factors for this market.
Take a Break and Get a sample of the report: https://www.emergenresearch.com/request-sample/75
Considerable numbers of the overall open excisional biopsy have been replaced by the minimally invasive biopsy technology in patients having the imaging-detected suspicious or the indeterminate breast lesions. With minimally invasive surgeries in the biopsy, higher precisions can be accumulated, which in turn helps in reducing the psychological burden that affects the patients and also helps reduce the overall cost by a significant margin.
Global Minimally Invasive Biopsy Technologies Market COVID-19 Analysis
The report offers an extensive analysis of the factors that are likely to influence the growth of the industry. The research study considers the COVID-19 pandemic a key growth influencing factor. The pandemic has negatively impacted the Minimally Invasive Biopsy Technologies industry through disruptions in global supply chains and grueling economic conditions. The report extensively analyzes the impact of the pandemic on the Minimally Invasive Biopsy Technologies market on a global as well as regional scale. To be updated, the report is furnished with the latest impact of the currently unfolding coronavirus pandemic on the Minimally Invasive Biopsy Technologies industry. The pandemic began in late 2019 and hit the world in early 2020, disrupting the normal lives and affecting every segment of the world. The report covers the impact of the pandemic on the Minimally Invasive Biopsy Technologies market and its key segment. The report also offers an initial and future assessment of the impact of the pandemic on the Minimally Invasive Biopsy Technologies market and offers revenue estimations in a post-COVID-19 scenario.
Revenue and cost profit analysis of major player dominating the Minimally Invasive Biopsy Technologies market
The report also takes into consideration the effect of the different restrictions imposed in different regions on the Minimally Invasive Biopsy Technologies industry and its key segments. It also offers a current and future impact analysis of the pandemic on the overall Minimally Invasive Biopsy Technologies market.
Key players in the market include Chronix Biomedical, Biocept, Inc., F. Hoffmann-La Roche Ltd, Mauna Kea Technologies, Veracyte, Inc., Thermo Fisher Scientific, NeoGenomics Laboratories, Inc., Abcodia Ltd., Adaptive Biotechnologies, and Owlstone Medical Ltd., among others.
Any information regarding report, Visit Here: https://www.emergenresearch.com/purchase-enquiry/75
The segmentation of the market is done on the basis of product types, application spectrum, and the key regions of the Minimally Invasive Biopsy Technologies market. Along with this, the report also provides extensive coverage of the key companies and their strategic schemes to gain a substantial market position.
The therapeutic application is further segmented into Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Blood Cancer, and Non-oncology Application. Minimally invasive breast biopsy (MIBB) has been highly recommended for the pre breast cancer diagnosis and checkup globally. The MIBB is expected to grow higher during the projected period as the number of breast cancer increases.
- Technology Outlook (Revenue: USD Billion; 2017-2027)
- Liquid Biopsy
- Optical Biopsy
- Brush Biopsy
- Pigmented Lesion Assays
- Breath Biopsy
- Brush Biopsy
- Therapeutic Application Outlook (Revenue: USD Billion; 2017-2027)
- Lung Cancer
- Breast Cancer
- Prostate Cancer
- Colorectal Cancer
- Blood Cancer
- Non-oncology Applications
- End-Use Verticals Outlook (Revenue: USD Billion; 2017-2027)
- Hospitals & Clinics
- Ambulatory Surgical Centers
- Cancer Research Institutes
The report offers a comprehensive overview of the global Minimally Invasive Biopsy Technologies market scenario pertaining to market value, volume, production and consumption rates, and market segmentation based on types, regions, and applications.
To get leading market solutions, visit the link below: https://www.emergenresearch.com/industry-report/minimally-invasive-biopsy-technologies-market
The Asia Pacific region, due to its immense rise in the breast & lung cancers & rising usage of the MIB technologies, is expected to accelerate with the fastest growth rate of 20.1% during the projected period 2020 to 2027.
Regional Outlook (Revenue: USD Billion; 2017-2027)
- North America
- Asia Pacific
- South Korea
- Rest of APAC
- Latin America
- Rest of LATAM
- Saudi Arabia
- Rest of MEA
Request customization of the report: https://www.emergenresearch.com/request-for-customization/75
Key Questions Addressed in the Report:
- Who are the leading players of the Minimally Invasive Biopsy Technologies industry?
- Which region is expected to dominate the market in the coming years?
- What are the key applications of the Minimally Invasive Biopsy Technologies market?
- Which segment is expected to garner traction during the coming years?
- Report Overview
1.1 Research Scope
1.2 Key Minimally Invasive Biopsy Technologies market segments
1.3 Target players
1.4 Market analysis by type
1.5 Market analysis by application
1.6 Key learning objectives
1.7 Report timeline
- Global Growth Trends
2.1 Global Minimally Invasive Biopsy Technologies market size
2.2 Latest trends of the Minimally Invasive Biopsy Technologies market by region
2.3 Key corporate trends
At Emergen Research, we believe in advancing with technology. We are a growing market research and strategy consulting company with an exhaustive knowledge base of cutting-edge and potentially market-disrupting technologies that are predicted to become more prevalent in the coming decade.
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: [email protected]
Facebook | LinkdIn | Twitter | Blogs